Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 19Phase NA 15Phase 1/2 13Phase 3 11Phase 4 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Tumor-Agnostic 3Classical hematology 3Thoracic 2Genitourinary 1Breast 1

Conditions

Neoplasms 53Neoplasm Metastasis 9Adenocarcinoma 3Neoplasms, Second Primary 2Carcinoma, Squamous Cell 2Carcinoma 1

Interventions

Pemetrexed 2Drug Therapy 2icotinib 1Gemcitabine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Adenocarcinoma × Tumor-Agnostic × Clear all
NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02194556 2014-07-18

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡